Oculis’ (OCS) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Oculis (NASDAQ:OCS) in a research note published on Tuesday,Benzinga reports. Chardan Capital currently has a $51.00 price objective on the stock.

Several other analysts also recently weighed in on the stock. Needham & Company LLC began coverage on shares of Oculis in a research report on Wednesday, August 27th. They set a “buy” rating and a $36.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a report on Wednesday, October 8th. HC Wainwright lifted their price objective on shares of Oculis from $33.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. Finally, Wall Street Zen downgraded Oculis from a “hold” rating to a “sell” rating in a research note on Sunday, September 21st. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $39.80.

Oculis Price Performance

Oculis stock opened at $19.29 on Tuesday. Oculis has a 1 year low of $14.00 and a 1 year high of $23.08. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -7.65 and a beta of 0.30. The firm has a 50-day moving average of $19.15 and a two-hundred day moving average of $18.62. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.55.

Oculis (NASDAQ:OCS) last issued its earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.10. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. The company had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.23 million. On average, research analysts forecast that Oculis will post -2.09 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

A number of hedge funds have recently added to or reduced their stakes in the business. Kestra Private Wealth Services LLC acquired a new stake in Oculis in the 1st quarter valued at about $234,000. Bosun Asset Management LLC purchased a new stake in shares of Oculis during the 2nd quarter worth approximately $378,000. Marshall Wace LLP purchased a new stake in Oculis in the second quarter valued at $393,000. Geode Capital Management LLC boosted its position in shares of Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares during the period. Finally, Bank of America Corp DE boosted its holdings in shares of Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after acquiring an additional 878 shares during the period. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.